Alpha Teknova, Inc.

NASDAQ:TKNO

Drug Manufacturers - Specialty & Generic

Healthcare
$7.88 +4.55%

+$0.23 today

Market cap
$495.68M
Beta
0.63
P/E (TTM)
-16.2
EPS (TTM)
-$0.32
52W Low $1.91High $6.68

Volume 0.30M

Average 0.13M

TKNO Pre-Tax Margin

Income before tax as a percentage of revenue.

Alpha Teknova, Inc.NASDAQ: TKNO

Pre-Tax Margin · Q1 FY2026 · quarter ended Mar 2026

Pre-tax margin widens to -40.7%

Pre-tax margin was -40.7% in Q1 FY2026, up 6.5 pp from a year earlier. On a trailing-twelve-month basis it was -40.9%, up 20.1 pp year over year. Over 3 fiscal years it widened by 76.8 pp.

Context

  • Pre-tax margin widened in 3 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-40.7%+7.6 pp QoQ
Last fiscal yearDec 2025
-42.5%+28.6 pp YoY
LTMMar 2026
-40.9%+20.1 pp YoY
Pre-Tax Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+6.5 pp——
1 year+28.6 pp——
3 years+76.8 pp——
5 years——
10 years——

Pre-Tax Margin history

Percent of revenue · from the income statement

Latest · FY2025
-42.5%
Year-over-year change
+28.6pp

Pre-Tax Margin vs competitors

How TKNO compares with its peers on the latest reported figures

  • TKNO's LTM Mar 2026 pre-tax margin of -40.9% is the 6th highest of the 8 companies compared; the peer median is -10.4%.
  • Its year-over-year change of +20.1 pp is the 2nd highest of 8, against a peer median of +2.3 pp.
  • Over three fiscal years its change of +76.8 pp compares with a peer median of -10.0 pp.
TKNO Competitors Peer median
Pre-Tax Margin for TKNO and competitors
Company Period LTM level YoY 3-year change
TECHBio-Techne CorporationLTM Sep 202618.5% +9.8 pp-10.0 pp
RGENRepligen CorporationLTM Jun 20266.6% +8.7 pp-18.9 pp
MLABMesa Laboratories, Inc.LTM Mar 20264.8% +2.3 pp+5.0 pp
BLFSBioLife Solutions, Inc.LTM Mar 2026-10.4% +1.8 pp-6.2 pp
AZTAAzenta, Inc.LTM Sep 2026-24.3% -23.6 pp-19.7 pp
TKNOAlpha Teknova, Inc.LTM Mar 2026-40.9% +20.1 pp+76.8 pp
MRVIMaravai LifeSciences Holdings, Inc.LTM Jun 2026-65.4% +96.3 pp-189.0 pp
LABStandard BioTools Inc.LTM Mar 2026-101.8% -20.3 pp+83.6 pp
Peer median (excluding TKNO) -10.4%+2.3 pp-10.0 pp

Competitors are the stored peer set for TKNO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue36.89M41.42M36.68M37.75M40.52M
Cost of Revenue19.27M23.94M26.39M30.51M27.08M
Gross Profit17.62M17.48M10.3M7.23M13.44M
Gross Margin47.8%42.2%28.1%19.2%33.2%
Research & Development4.31M7.74M5.57M2.76M2.2M
Selling, General & Admin24.17M37.45M34.78M29.47M27.07M
Operating Expenses29.63M67.14M45.86M33.38M30.42M
Depreciation & Amortization2.88M3.17M5.66M6.58M6.34M
EBITDA(9.17M)(25.69M)(25.54M)(19.57M)(10.15M)
EBITDA Margin-24.8%-62.0%-69.6%-51.8%-25.0%
Operating Income(12.01M)(49.66M)(35.56M)(26.15M)(16.98M)
Operating Margin-32.5%-119.9%-96.9%-69.3%-41.9%
Interest Income0213K000
Interest Expense589K0833K687K710K
Other Income / Expenses(629K)268K(1.52M)(687K)(225K)
Income Before Tax(12.64M)(49.39M)(37.08M)(26.83M)(17.2M)
Pre-Tax Margin-34.3%-119.2%-101.1%-71.1%-42.5%
Income Tax Expense(2.83M)(1.92M)(298K)(88K)58K
Net Income(9.8M)(47.47M)(36.78M)(26.75M)(17.26M)
Net Margin-26.6%-114.6%-100.3%-70.9%-42.6%
EPS (Basic)(0.35)(1.69)(1.16)(0.57)(0.32)
EPS (Diluted)(0.35)(1.69)(1.16)(0.57)(0.32)
Weighted Avg Shares28.01M28.08M31.82M46.75M53.48M
Weighted Avg Shares (Diluted)28.01M28.08M31.82M46.75M53.48M

Alpha Teknova, Inc.

NASDAQ:TKNO

Intrinsic Alpha fair value

Locked

Current Price

$7.88

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.